Danish firm Bavarian Nordic has a portfolio of patents for vaccines and cancer treatments, but likes to keep some of its cards close to its chest, as LSIPR finds out.
One week after the September 11 attacks in 2001, letters containing anthrax spores started appearing in the US postal system. Infected envelopes were sent to media offices and two US senators. The attack killed five people in what the Federal Bureau of Investigation described as one of the worst biological attacks in American history.
The incident sparked fears of a similar attack, followed by calls for a strategy to manage potential outbreaks of infectious diseases, including smallpox.
Although smallpox was declared officially eradicated after a global vaccination programme led by the World Health Organization, the virus still exists in laboratory archives and repositories controlled by the UN.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at email@example.com.
If you have any technical issues please email tech support.
Trade secrets, IP strategy, Bavarian Nordic, Vaccines, Smallpox